Answers are grounded in this paper and cite their sources.
We are grateful to Spencer and Bhargava for their careful commentary on our review and for highlighting children in whom olfactory dysfunction is especially likely to be missed: those with congenital, syndromic, neurodevelopmental or craniofacial conditions (1)(2)(3)(4). Their contribution addresses a relevant gap in paediatric olfactory medicine, since these children may neither report smell loss nor reliably complete conventional psychophysical tests (1,(5)(6)(7)(8).We interpret their proposal not as a separate modification of the original diagnostic pathway, but as a refinement within a broader clinical model guided by risk-based case finding, feasibility-based testing and treatment-oriented classification.Spencer and Bhargava correctly point out that the absence of a smell complaint should not reassure clinicians when a child belongs to a high-risk group (1). The epidemiological data cited in their commentary, including the observation that congenital causes account for roughly two-thirds of paediatric olfactory dysfunction and that olfactory impairment may be detected in over 80% of children with CHARGE syndrome when all assessment modalities are considered, support a more systematic, risk-triggered approach (1,4). In syndromes such as CHARGE, Kallmann syndrome, 22q11.2 deletion syndrome and Bardet-Biedl syndrome, olfactory dysfunction may remain unnoticed while attention is directed toward hearing, vision, endocrine function, airway, feeding or developmental issues (1,2,(9)(10)(11).This strengthens the first step of the original diagnostic pathway (2). Congenital or syndromic diagnoses should not be recorded merely as background information; in selected children, they should actively trigger olfactory enquiry, safety counselling and, when appropriate, multidisciplinary assessment. We also agree that, where olfactory dysfunction is documented at high prevalence within a given syndrome, its role may eventually warrant discussion within revised diagnostic criteria, although this remains a matter for future consensus rather than for individual clinical algorithms (1).We agree that conventional psychophysical tests have important limitations in some children (5)(6)(7)(8). The operational criteria proposed for a "developmental bypass" pathwaynon-verbal developmental age below approximately 4 years, inability to follow a two-step command, uncorrected bilateral choanal atresia or prolonged enteral feeding without established oral intakeare a reasonable starting point for clinical discussion (1). As the authors acknowledge, however, these thresholds are practical rather than formally validated, and require prospective evaluation before incorporation into routine algorithms.The proposed bypass should not be restricted to congenital syndromes alone. Developmental age, language comprehension, attention span, behavioural cooperation, nasal airflow and feeding route may all influence test validity (5-8). A child with autism spectrum disorder, severe attention difficulties or marked nasal obstruction may produce unreliable results even without a classic congenital syndrome. Conversely, some older children with syndromic conditions may complete adapted psychophysical testing successfully. The relevant distinction should therefore be between testing conditions that can provide reliable information and those that cannot.When psychophysical testing is feasible, age-appropriate and culturally adapted tools remain central for diagnosis and follow-up (6)(7)(8). When it is not feasible, clinicians should combine structured history, feeding and safety assessment, nasal endoscopy, cautious parental report, selected imaging and, where available, objective electrophysiological investigations (1,2,5,13). We adopt the term "developmental bridge", as proposed by Spencer and Bhargava, to describe reassessment toward psychophysical testing as developmental or communicative abilities improve (1).Magnetic resonance imaging is valuable in selected patients, particularly when congenital or central olfactory dysfunction is suspected (2). It may identify olfactory bulb or tract hypoplasia/aplasia, anterior skull base abnormalities, forebrain malformations or other lesions relevant to etiological classification. Nonetheless, imaging should not substitute functional assessment, since morphology and function may not always overlap (12).Olfactory event-related potentials (OERPs) are among the most promising objective tools for children who cannot provide reliable behavioural responses (13). We support the authors' call for OERP technology to move from a research tool toward routine clinical practice, and join their call for multicentre efforts to standardize stimulation and recording protocols, establish paediatric normative data and define clinically meaningful thresholds (1,5,13). Without these steps, clinical translation will remain limited.While congenital and syndromic olfactory dysfunctions are diagnostically vulnerable, inflammatory and obstructive causes remain relevant because they may be modifiable (2)(3)(4). Adenoid hypertrophy, allergic rhinitis, chronic rhinosinusitis, nasal polyposis, cystic fibrosis-related sinonasal disease and post-infectious olfactory dysfunction should be actively identified, since medical, surgical or rehabilitative interventions may improve nasal patency, inflammation, food enjoyment and quality of life (2,14,15).Refinement of the congenital arm should therefore not narrow the diagnostic perspective. A paediatric algorithm should identify hidden congenital dysfunction while preserving attention to reversible causes. Retronasal olfaction, appetite, feeding behaviour and family observations may be particularly informative in children with chronic nasal obstruction or inflammatory airway disease, although standardized paediatric assessment remains limited (2,14,15).We suggest that Spencer and Bhargava's proposals can be integrated into a riskand feasibility-based model with treatment-oriented classification. First, risk-based triggers should prompt olfactory evaluation even without spontaneous complaint (1,(9)(10)(11). Second, feasibility-based assessment should determine whether psychophysical testing is reliable or whether alternative tools are required (5)(6)(7)(8). Third, classification should distinguish congenital or sensorineural conditions, in which counselling, safety measures and follow-up are central, from inflammatory, obstructive, infectious or traumatic conditions in which treatment may modify outcomes (2,14,15). The proposed integration is summarized in Figure 1. This model maintains the pragmatic structure of the original algorithm while accounting for developmental constraints. Future progress will require multicentre validation of age-adapted psychophysical tests, standardization of paediatric OERP protocols, longitudinal evaluation of syndromic populations and stronger incorporation of olfactory assessment into multidisciplinary paediatric care (3,5,6,13).In conclusion, we welcome Spencer and Bhargava's commentary as an important contribution to diagnostic equity in paediatric olfactory dysfunction. Their proposal should not replace the existing clinical pathway but enrich it by making explicit a principle central to paediatric practice: assessment should follow the child's risk profile, developmental abilities and potential for therapeutic benefit.
No takes yet. Share an insight, caveat, or question.
Trecca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: